Mortality in sickle cell patients on hydroxyurea therapy

Sule M. Bakanay, Erin Dainer, Betsy Clair, Adekunle Adekile, Lisa H Daitch, Leigh Wells, Leslie Holley, David Smith, Abdullah Kutlar

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

The efficacy of hydroxyurea (HU) and its role in the reduction in mortality in sickle cell patients has been established. Nevertheless, many patients still die of complications of this disease while on HU. Of the 226 patients treated with HU at our center, 38 died (34 of sickle cell-related causes). Acute chest syndrome (ACS) was the most common (35%) cause of death. Deceased and surviving patients did not differ significantly in average HU dose, baseline fetal hemoglobin (Hb F), or maximum Hb F response. However, the deceased patients were significantly older when HU was instituted, were more anemic, and more likely to have BAN or CAM haplotypes. They also had significantly higher serum blood-urea-nitrogen (BUN) and creatinine levels. Sickle cell patients who die while on HU therapy may represent a subgroup of older patients, possibly with more severe disease and more severe organ damage. Such patients need early identification and prompt HU institution.

Original languageEnglish (US)
Pages (from-to)545-547
Number of pages3
JournalBlood
Volume105
Issue number2
DOIs
StatePublished - Jan 15 2005

Fingerprint

Hydroxyurea
Mortality
Fetal Hemoglobin
Therapeutics
Acute Chest Syndrome
Computer aided manufacturing
Blood Urea Nitrogen
Urea
Creatinine
Haplotypes
Blood
Nitrogen
Cause of Death
Serum

ASJC Scopus subject areas

  • Hematology

Cite this

Bakanay, S. M., Dainer, E., Clair, B., Adekile, A., Daitch, L. H., Wells, L., ... Kutlar, A. (2005). Mortality in sickle cell patients on hydroxyurea therapy. Blood, 105(2), 545-547. https://doi.org/10.1182/blood-2004-01-0322

Mortality in sickle cell patients on hydroxyurea therapy. / Bakanay, Sule M.; Dainer, Erin; Clair, Betsy; Adekile, Adekunle; Daitch, Lisa H; Wells, Leigh; Holley, Leslie; Smith, David; Kutlar, Abdullah.

In: Blood, Vol. 105, No. 2, 15.01.2005, p. 545-547.

Research output: Contribution to journalArticle

Bakanay, SM, Dainer, E, Clair, B, Adekile, A, Daitch, LH, Wells, L, Holley, L, Smith, D & Kutlar, A 2005, 'Mortality in sickle cell patients on hydroxyurea therapy', Blood, vol. 105, no. 2, pp. 545-547. https://doi.org/10.1182/blood-2004-01-0322
Bakanay SM, Dainer E, Clair B, Adekile A, Daitch LH, Wells L et al. Mortality in sickle cell patients on hydroxyurea therapy. Blood. 2005 Jan 15;105(2):545-547. https://doi.org/10.1182/blood-2004-01-0322
Bakanay, Sule M. ; Dainer, Erin ; Clair, Betsy ; Adekile, Adekunle ; Daitch, Lisa H ; Wells, Leigh ; Holley, Leslie ; Smith, David ; Kutlar, Abdullah. / Mortality in sickle cell patients on hydroxyurea therapy. In: Blood. 2005 ; Vol. 105, No. 2. pp. 545-547.
@article{0e36766b9aac4fc38cab7ac3063cb0a4,
title = "Mortality in sickle cell patients on hydroxyurea therapy",
abstract = "The efficacy of hydroxyurea (HU) and its role in the reduction in mortality in sickle cell patients has been established. Nevertheless, many patients still die of complications of this disease while on HU. Of the 226 patients treated with HU at our center, 38 died (34 of sickle cell-related causes). Acute chest syndrome (ACS) was the most common (35{\%}) cause of death. Deceased and surviving patients did not differ significantly in average HU dose, baseline fetal hemoglobin (Hb F), or maximum Hb F response. However, the deceased patients were significantly older when HU was instituted, were more anemic, and more likely to have BAN or CAM haplotypes. They also had significantly higher serum blood-urea-nitrogen (BUN) and creatinine levels. Sickle cell patients who die while on HU therapy may represent a subgroup of older patients, possibly with more severe disease and more severe organ damage. Such patients need early identification and prompt HU institution.",
author = "Bakanay, {Sule M.} and Erin Dainer and Betsy Clair and Adekunle Adekile and Daitch, {Lisa H} and Leigh Wells and Leslie Holley and David Smith and Abdullah Kutlar",
year = "2005",
month = "1",
day = "15",
doi = "10.1182/blood-2004-01-0322",
language = "English (US)",
volume = "105",
pages = "545--547",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - Mortality in sickle cell patients on hydroxyurea therapy

AU - Bakanay, Sule M.

AU - Dainer, Erin

AU - Clair, Betsy

AU - Adekile, Adekunle

AU - Daitch, Lisa H

AU - Wells, Leigh

AU - Holley, Leslie

AU - Smith, David

AU - Kutlar, Abdullah

PY - 2005/1/15

Y1 - 2005/1/15

N2 - The efficacy of hydroxyurea (HU) and its role in the reduction in mortality in sickle cell patients has been established. Nevertheless, many patients still die of complications of this disease while on HU. Of the 226 patients treated with HU at our center, 38 died (34 of sickle cell-related causes). Acute chest syndrome (ACS) was the most common (35%) cause of death. Deceased and surviving patients did not differ significantly in average HU dose, baseline fetal hemoglobin (Hb F), or maximum Hb F response. However, the deceased patients were significantly older when HU was instituted, were more anemic, and more likely to have BAN or CAM haplotypes. They also had significantly higher serum blood-urea-nitrogen (BUN) and creatinine levels. Sickle cell patients who die while on HU therapy may represent a subgroup of older patients, possibly with more severe disease and more severe organ damage. Such patients need early identification and prompt HU institution.

AB - The efficacy of hydroxyurea (HU) and its role in the reduction in mortality in sickle cell patients has been established. Nevertheless, many patients still die of complications of this disease while on HU. Of the 226 patients treated with HU at our center, 38 died (34 of sickle cell-related causes). Acute chest syndrome (ACS) was the most common (35%) cause of death. Deceased and surviving patients did not differ significantly in average HU dose, baseline fetal hemoglobin (Hb F), or maximum Hb F response. However, the deceased patients were significantly older when HU was instituted, were more anemic, and more likely to have BAN or CAM haplotypes. They also had significantly higher serum blood-urea-nitrogen (BUN) and creatinine levels. Sickle cell patients who die while on HU therapy may represent a subgroup of older patients, possibly with more severe disease and more severe organ damage. Such patients need early identification and prompt HU institution.

UR - http://www.scopus.com/inward/record.url?scp=11244348903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=11244348903&partnerID=8YFLogxK

U2 - 10.1182/blood-2004-01-0322

DO - 10.1182/blood-2004-01-0322

M3 - Article

VL - 105

SP - 545

EP - 547

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -